Abrocitinib and Cangrelor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abrocitinib
Cangrelor
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines both make bleeding more likely, so using them together can add up. Abrocitinib (Cibinqo) is a pill for eczema that can affect your platelets, the tiny cells that help your blood clot. Cangrelor (Kengreal) is a strong IV blood thinner given in the hospital to keep platelets from sticking together. Combining them raises the chance of bruising or bleeding.
Because of this, they are not meant to be used together during the first 3 months of starting abrocitinib. The good news is your care team knows about this and can plan around it. Always tell your doctors and pharmacist about every medicine you take.
Mechanism: Additive pharmacodynamic effect on hemostasis. Cangrelor is a direct-acting reversible P2Y12 platelet inhibitor; abrocitinib (a JAK1 inhibitor) can reduce platelet counts, particularly early in therapy. Neither requires metabolic activation here, so this is a PD, not PK, interaction.
- Direction: Additive increase in bleeding risk.
- Severity: Contraindicated during the first 3 months of abrocitinib therapy (antiplatelet agents other than low-dose aspirin, 81 mg/day or less).
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Avoid concurrent use in the first 3 months; monitor for bleeding and check platelet counts if co-exposure occurs.
What happens
Increased risk of bleeding
Interaction Deep Dive
During the initial 3 months of therapy, giving abrocitinib together with antiplatelet drugs is contraindicated because of a heightened bleeding risk, with the exception of low-dose aspirin (81 mg per day or less)1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
Both drugs raise bleeding risk, so the labeling advises not combining them during the first 3 months of abrocitinib treatment (antiplatelet agents other than low-dose aspirin of 81 mg daily or less).
- Keep taking your medicines exactly as prescribed and do not stop anything on your own.
- Since cangrelor is given during a hospital procedure, make sure that team knows you take abrocitinib so they can choose the safest plan.
- Watch for and report unusual bruising, bleeding gums, nosebleeds, blood in urine or stool, or bleeding that will not stop.
- Ask your pharmacist or prescriber before adding any new blood thinner or antiplatelet drug.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abrocitinib and Cangrelor together?
Abrocitinib and cangrelor together add up to a higher bleeding risk and are considered contraindicated during the first 3 months of abrocitinib therapy. Make sure your care team knows you take both so they can plan safely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Cangrelor interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Cangrelor interaction managed?
Both drugs raise bleeding risk, so the labeling advises not combining them during the first 3 months of abrocitinib treatment (antiplatelet agents other than low-dose aspirin of 81 mg daily or less). Keep taking your medicines exactly as prescribed and do not stop anything on your own. Since cangrelor is given during a hospital procedure, make sure that team knows you take abrocitinib so they can… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abrocitinib or Cangrelor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Abrocitinib
Keep reading about Cangrelor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist